KIRYAT ONO, Israel & NEW YORK--(BUSINESS WIRE)--Sept. 19, 2006--GammaCan International, Inc. (OTCBB: GCAN) today announced that physicians from Tel Ha'Shomer Hospital in Tel Aviv, and GammaCan will present top line findings of the GC 101 trial at the 5th Annual Congress on Autoimmunity taking place in Sorrento Italy from November 29th through December 3rd, 2006. The presentation and abstract are titled "Efficacy and Safety of IVIG Intravenous Immunoglobulin in Patients with Metastatic Melanoma." The senior authors are Drs. Jacob Schachter, MD and Uriel Katz, MD, PhD and the study was fully funded by GammaCan International, Inc.
